Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Poxel S.A.
  6. Company
    POXEL   FR0012432516

POXEL S.A.

(POXEL)
  Report
Real-time Quote. Real-time Euronext Paris - 06/18 11:35:08 am
6.96 EUR   -2.25%
06/01POXEL  : Corporate Presentation
PU
05/21Today on Wall Street: Poor manufacturing data boosts indexes
05/14POXEL  : Corporate Profile May 2021
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Poxel S.A.
Poxel SAS is a France-based company principally engaged in the biopharmaceutical sector. The Company develops drugs with a focus on Type 2 diabetes. The Company aims at developing drugs from preclinical to phase 2 clinical proof of concept. Its lead product, Imeglimin, is in clinical phase 2 study for Type 2 diabetes indication. A direct activator of AMPK for the treatment of Type 2 diabetes has started its preclinical development, and other projects in the research phase target diabetes and other metabolic diseases with small molecules that have a disease-modifying mechanism of action. Poxel SAS was spun out from Merck Serono. The Company cooperates with the Laboratory for Fundamental and Applied Bioenergetics, Sumitomo Dainippon Pharma, Joseph Fourier University and Department of Cell Physiology and Metabolism at the University of Geneva, Switzerland, among others.

Number of employees : 53 people.
Sales per Business
20192020Delta
EUR (in Million)%EUR (in Million)%
Innovative Molecules for Treatment of Metabolic Diseases26.56100%6.81100% -74.37%
Sales per region
20192020Delta
EUR (in Million)%EUR (in Million)%
France26.56100%6.81100% -74.37%
Managers
NameAgeSinceTitle
Thomas Kuhn462009Chief Executive Officer & Director
Anne Renevot--Chief Financial Officer & Executive Vice President
Sophie Hallakou-Bozec, Dr.-2009Senior Vice President-Research & Development
Takashi Kaneko, Dr.--Senior Vice President-Medical
David E. Moller, Dr.--Chief Scientific Officer & Executive VP
Sebastien Bolze, Dr.--Chief Operating Officer & Executive Vice President
Mohammed Khoso Baluch622013Independent Director
Richard N. Kender642015Independent Director
Pascale Boissel542015Independent Director
Janice Bourque632016Independent Director
Members of the board
NameAgeSinceTitle
Pierre Legault592016Chairman
Thomas Kuhn462009Chief Executive Officer & Director
Mohammed Khoso Baluch622013Independent Director
Richard N. Kender642015Independent Director
Pascale Boissel542015Independent Director
Janice Bourque632016Independent Director
Kumi Sato-2017Independent Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 28,495,523 22,811,264 80.1% 0 0.0% 80.1%
Shareholders
NameEquities%
Andera Partners SCA 2,829,185 9.89%
BPIFrance Investissement SAS 2,175,573 7.60%
Bpifrance Participations SA /PRIVATE EQUITY/ 2,055,721 7.19%
Thomas Kuhn 1,505,965 5.26%
Roivant Sciences Ltd. 1,430,406 5.00%
Deuterx LLC 1,289,711 4.51%
Mandarine Gestion SA 100,000 0.35%
La Banque Postale Asset Management SA 61,029 0.21%
Tocqueville Finance SA 61,029 0.21%
CPR Asset Management SA 55,673 0.19%
Holdings
NameEquities%Valuation
Poxel S.A. (POXEL) 39,0820.14%346,431 USD
Company contact information
Poxel SA
259/261, avenue Jean Jaurès
Lyon, Auvergne-Rhone-Alpes 69007

Phone : +33.4.37.37.20.12
Fax : +33.4.37.70.88.15
Web : http://www.poxel.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Poxel S.A.
Sector Bio Therapeutic Drugs
1st jan.Capitalization (M$)
POXEL S.A.9.43%236
GILEAD SCIENCES, INC.14.33%83 541
WUXI APPTEC CO., LTD.24.70%63 775
REGENERON PHARMACEUTICALS11.35%55 705
BIONTECH SE160.57%51 304
VERTEX PHARMACEUTICALS-20.52%48 628
BEIGENE, LTD.24.54%29 784
GENMAB A/S10.52%28 359
ARGENX SE10.41%16 252
HUALAN BIOLOGICAL ENGINEERING INC.-14.44%10 217
NEUROCRINE BIOSCIENCES, INC.4.87%9 504
DENALI THERAPEUTICS INC.-11.97%8 936
ARROWHEAD PHARMACEUTICALS, INC.11.61%8 914
MIRATI THERAPEUTICS, INC.-24.17%8 568
REMEGEN CO., LTD.34.63%8 070
ACCELERON PHARMA INC.0.23%7 784
ASCENDIS PHARMA A/S-15.49%7 587
FATE THERAPEUTICS, INC.-11.77%7 544
EXELIXIS, INC.11.66%7 023
GW PHARMACEUTICALS PLC89.72%6 907
AKESO, INC.62.63%6 504